P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A123.2-A124
10.1136/gutjnl-2025-bsg.193